Expert Analysis

Clinical Update on First-Line Antiretroviral Therapy

Source: CCO Independent Conference Coverage of the 2007 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Clinical Update on First-Line Antiretroviral Therapy

Faculty:
David A. Cooper, MD, DSc Joel E. Gallant, MD, MPH Kimberly Y. Smith, MD, MPH

CME CREDIT INFORMATION

Release Date: 04/26/07

Expiration Date: 04/25/08

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.5 contact hours (0.15 CEUs)

Registered Nurses: 1.6 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the results of studies investigating the use of boosted PIs in the treatment of pregnant HIV-infected women
Discuss whether the rate of initial viral decay is associated with long-term virologic outcomes of therapy
Summarize the results of recent studies utilizing FDA-approved and investigational antiretrovirals as first-line regimens in HIV-infected patients
Specify considerations that may influence the choice of first-line antiretroviral regimens in resource-limited settings
Describe recent data on the predictive value of viral load in determining CD4+ cell count decline and disease progression

Topics covered include:

Use of Boosted PIs in HIV-Infected Pregnant Women
TMC278 vs Efavirenz Among Treatment-Naive Patients
Viral Decay With Efavirenz- vs Lopinavir/Ritonavir-Based Therapy in ACTG 5142
Observational Comparisons of Efavirenz- vs Lopinavir/Ritonavir-Based Regimens
Once-Daily vs Twice-Daily Lopinavir/Ritonavir in Treatment-Naive Patients
Tshepo Study: Directly Observed HAART Among Treatment-Naive HIV-Infected Individuals in Botswana
NORA Study: Abacavir- vs Nevirapine-Based Treatment in Uganda
GESIDA 3903: Didanosine/Lamivudine vs Zidovudine/Lamivudine With Efavirenz
Early Virologic Failure With Once-Daily Regimen of Lamivudine, Tenofovir, and Nevirapine
Baseline Viral Load as a Predictor of HIV Disease Progression
Influence of Race and Sex on Treatment Outcomes
Conclusion: Current Directions in First-Line Therapy

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.